Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Companion Diagnostic for Tagrisso Now Covered by Health Insurance
April 11, 2016
- Ethical Drug Sales Jump 15.6% in February: Crecon Report
April 11, 2016
- Ex-Genzyme Japan Chief Hideyuki Ashikaga to Lead Baxter Japan
April 11, 2016
- Astellas Introduces 1st Major Reform of Domestic Marketing System in 10 Years to Understand Issues Specific to Each Area: Marketing Head
April 8, 2016
- Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
- Bayer Japan Taps Big Data to Shorten Trial Site Selection by 1-2 Months; 2015 Sales Up 12.2%
April 7, 2016
- Takecab Most Promoted Drug in February: Anterio
April 7, 2016
- Terumo Preparing to Launch HeartSheet; Sees Room for Improvements in Production and Quality Control
April 7, 2016
- MSD, Alfresa, Aerosense to Collaborate in Developing a Drug Delivery Business Using Drones
April 7, 2016
- Mylan Japan Labor Union Raps Management over “Effective Dismissal”, No Progress Made in 1st Round of Negotiations
April 6, 2016
- Daiichi Sankyo Joins Portola’s Factor Xa Antidote Consortium in Japan
April 6, 2016
- Daiichi Sankyo, Asahikawa Medical Univ. to Conduct Joint Research on New Stem Cells with Funding from Mitsubishi UFJ Capital
April 6, 2016
- JT, Torii Aim to File Japan NDA for Gilead’s Anti-HIV Drug in July-September
April 6, 2016
- Astellas Strikes New Research Pact with AIST for Chagas’ Disease
April 5, 2016
- GSK Keeps Its JCR Stake at 25%, Eyes Collaboration in Blood-Brain Barrier Technology
April 4, 2016
- Asahi Kasei Pharma Licenses TrkA Inhibitors from Array BioPharma
April 4, 2016
- Meiji Seika Pharma Gets Rights to Distribute Ultibro, Seebri in Japan; Novartis to Continue Copromotion
April 4, 2016
- Astellas Completes Transfer of Dermatology Biz to LEO Pharma
April 4, 2016
- Ex-Pfizer Japan Exec Matsumori to Lead Takeda-Teva JV
April 4, 2016
- Nichi-Iko Gets Global Rights to Rituximab Biosimilar from S. Korea’s Aprogen
April 4, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…